In terms of impact on and cost to society psychiatric disorders are among the most important health problems of today. Current estimates from the US suggest that the collective cost of psychiatric diseases could amount to one-third of the total health care budget with a cumulative lifetime prevalence of 30%. While undoubtedly improvements have been made in the diagnosis and treatment of at least the symptoms of mental illness, there has been frustratingly little progress in elucidating the molecular mechanisms. However, a fundamentally different approach to study molecular mechanisms of psychiatric diseases is developing as a result of technological advances in expression profiling methods. This comprises the investigation of the expressed disease 'phenotypes', developing from the differential gene and protein expression in the central nervous system as a result of the complex interaction between genetic predisposition and environmental modulation. This paper will focus on proteomics, expression profiling at the protein level, reviewing some of the available tools and their application in the molecular analysis of psychiatric disease.
INTRODUCTION
Psychiatric disorders are among the most important health problems of today with respect to societal cost. Because in many cases there is no perception of an acute threat to life, mental illnesses do not get the public attention of cardiovascular disease or cancer. However, current estimates from the US suggest that the collective cost of psychiatric diseases could amount to one-third of the total health care budget with a cumulative lifetime prevalence of 30% [1] . The most frequent illnesses in adults in the United States are depressive disorders and anxiety disorders, both of which affect up to 20 million or 10 % of the adult population each year. Greater than 1 % of the adult population has schizophrenia and 1 in 1000 children is diagnosed with autism [2] . These figures still understate the burden of psychiatric disorders on society, because mental illnesses often affect the young, while being chronic and/or recurrent. Therefore the overall impact on people's work and private life is enormous.
Undoubtedly major progress has been made in the last few years in the diagnosis and psychopharmacological treatment of at least the symptoms of mental illness. At the same time, the molecular mechanism underlying the disease process has remained enigmatic in most cases [1, 3] . Consequently, treatment focuses on known but limited modulatory mechanisms such as the *Address correspondence to this author at the Novartis Institutes for Biomedical Research, WSJ-88. 8 .05, CH-4002 Basel, Switzerland, Tel.: +41 61 3249882; Fax: +41 61 3244249; E-mail: johannes.voshol@pharma.novartis.com dopamine system, which influences psychosis in schizophrenia [3] . In some cases where there is a notable genetic disease component, particularly in schizophrenia and bipolar disorder, but also in autism, a significant number of chromosomal 'hotspots' have been identified in families with a distinct prevalence of the disease [1, 4, 5] . While this does represent a first step towards defining molecular targets, the genetic approach has proven to be very cumbersome. Linkage analysis has severe limitations for complex, multigenic diseases. For example, in schizophrenia many loci on at least 12 different chromosomes have been implicated in the disease [1, 5] , unfortunately hardly any of them in more than a single study. Even the most convincing hits with LOD scores >6 [6] were subsequently invalidated in another population [7] . Most likely, even within a relatively homogeneous population, a hotspot may represent only one of the multifactorial aspects of the disease. Moreover, the impact of environmental influences is ignored, which is a major shortcoming since e.g. in schizophrenia the concordance between identical twins is 'only' about 50 %, illustrating the importance of factors that are not genetic in nature [8] . Another problem of linkage analysis is that of resolution: the identified linkage regions are large, usually greater than 1 cM. Thus even with the knowledge of the exact genome sequence of that region, there will be up to hundreds of (predicted) genes to analyze within a single hotspot. Figure 1 . Proteome analysis. A schematic overview of the workflow of a proteome analysis, using 2D electrophoresis as separation method. The sample preparation step aims to extract as many proteins as possible, using tissue disruption and strong solubilizing agents. The protein separation method should have a high resolution to get the maximum analysis depth. During the differential analysis control and disease states are compared and differences selected for identification by mass spectrometry. In an LC-MS method, differential analysis and identification can be merged or even reversed. Finally, differences are confirmed and validated, e.g. in an existing or newly created disease model. One attractive possibility is to characterize and optimize a newly created disease model, e.g. a knock-out, by a full proteomic analysis. Throughout the process, informatics plays a key role, from the sample tracking database and image analysis of 2D gels to protein identification based on MS data.
Instead of looking only at the genetic predisposition, we can now study many disease 'phenotypes' in parallel, developing from disease-associated differential gene and protein expression in the central nervous system. This review will focus on proteomics, expression profiling at the protein level, in the context of psychiatric diseases.
Proteomics and Proteome Complexity

Overview
With the completion of the genome sequences from a number of species, including human, an estimation of the number of encoded genes in the genome is now possible. Evidently, the complexity is dramatically higher at the protein (proteome) level than expected from the number of genes (Table I) . While in prokaryotes the 'one gene one protein' concept might hold some validity, in humans the purported 30'000-50'000 genes potentially encode for a vast number of different proteins (Table I) . Temporal and spatial specificity is achieved by regulation of protein expression at several points during DNA transcription, processing to mRNA and subsequent translation into polypeptide chains. Only after folding and post-translational modifications, such as proteolytic processing, phosphorylation and glycosylation, functional proteins are formed. The resulting degree of complexity implies the need for a series of highly efficient, sensitive and rapid analytical techniques to provide qualitative and quantitative information. These techniques form the basis of proteomic sciences, which involve the identification, and characterization of proteins as a complement to genomics. Proteome analyses will ultimately lead to the identification of new therapeutic targets and surrogate markers and provide completely new insights in the initiation and progression of diseases.
There are several experimental phases during differential proteome analysis, as schematically depicted in Fig. (1) . First, in a comparative analysis, the proteins expressed by a particular organism, tissue or cell under "normal" conditions need to be extracted, separated and compared to the protein expression of the same organism, tissue or cell under different conditions, e.g. after drug treatment or in a disease state. The separation and visualization of these complex protein mixtures is commonly performed using two-dimensional polyacrylamide gel electrophoresis (2D-PAGE, 2D electrophoresis) [9] , but recent advances in micro-HPLC and capillary electrophoretic methods may develop into alternatives to 2-D PAGE [10] .
Comparison of the protein patterns between the different states, e.g. by image analysis of the 2D gels or comparison of chromatographic profiles, are then used to discover the differentially expressed protein species. Independent of the separation method, the exquisite precision of mass measurement by mass spectrometry (MS) is the method of choice to provide an unequivocal identification of the protein of interest as well as for subsequent in-depth characterization, for example with respect to differences in post-translational modifications [11] . Although strictly speaking not part of the proteomics analysis, the biological relevance of the observed differences can only be evaluated by in vitro and in vivo confirmation and validation.
Protein Separation Methods
Two-dimensional gel electrophoresis Fig. (2) is currently the only method capable of simultaneously separating complex mixtures of thousands of proteins, as found in biological samples [12] . The first dimension of 2D-PAGE is isoelectric focusing (IEF), during which proteins are separated in an immobilized pH gradient (IPG) until they reach the pH of the stationary phase where their net charge is zero, also referred to as the isoelectric point (pI) of the protein. In the second dimension the proteins are further separated orthogonally by electrophoresis in the presence of sodium dodecyl sulfate (SDS-PAGE) based on their relative molecular mass. Since 2D-PAGE is the method that has been applied in the few published proteomic analyses related to psychiatric disease, this method will be discussed here in some detail.
The original 2D electrophoresis separates protein along a gradient of pH 3-10 in the first dimension. Thus a whole tissue or cell extract is separated on one gel with a relatively low resolution separation, resulting in the visualization of around 1500-2500 protein species depending on the detection sensitivity. Though there is no precise information on the number of different proteins simultaneously expressed, it is clear that coverage has to be higher for a meaningful proteome analysis. There are two ways of increasing the resolution and the depth of analysis. One is to use larger format gels on which up to 9,000 proteins have been reported to be detectable [13] . This separation system has the disadvantage that the components are not commercially available and the handling of gels is challenging. The alternative is to use standard 20 x 25 cm two-dimensional gels, but in combination with narrow-range pH gradients [14, 15] . This allows a resolution of over 10,000 protein species from a single sample [12] as well as a high loading capacity, yielding detection of proteins down to low ng levels corresponding to a few hundred copies per cell of a lymphoid cell line model system [16] . Twodimensional electrophoresis is not equally suitable for all classes of proteins. The main limitation of the method is the lack of coverage of proteins with extreme properties, such as hydrophobic molecules found in the cell membrane or highly charged proteins. These limitations are fundamental to separation at the protein level, because basic characteristics of proteins like charge, size and solubility are so variable that a 'universal' protein separation technique does not exist. Some of these difficulties can be circumvented by converting protein extracts to peptides by proteolytic -usually trypticdigestion prior to fractionation.
Peptide separation can be performed with high efficiency using liquid chromatography (LC) methods which can be automated and directly coupled with mass spectrometry. The power of peptide-based methods is that even proteins with extreme properties will produce some peptides that are amenable to LC separation. However, on average, tryptic cleavage will generate at least 30 peptides per protein and thus increase the complexity of the sample dramatically. To facilitate fractionation and identification, the number of peptides can be reduced by affinity selection of those containing a specific amino acid or modification. The prototype of such a method is the isotope-coded affinity tag (ICAT) approach, which not only allows for enrichment of Cys-containing peptides, but also for MS-based quantification through the addition of an isotope tag [10, 17] . A clear disadvantage of analyzing peptides is that fundamental characteristics of the intact parent protein, such as molecular weight and isoelectric point are lost. This renders the detection of multiple, e.g. phosphorylated, isoforms of a protein which can have completely different activities or functions [18] impossible. Therefore no proteomic analysis is complete without insight at the protein level.
Protein Visualization and Identification
Visualization of protein spots on gels is commonly achieved by various post-separation staining methods, the most important of which are Coomassie Blue, silver or fluorescent dyes. Of these silver staining is the most sensitive, reaching a detection level of about 1 ng of protein, but an important drawback is that it is not an endpoint staining. Thus for differential analysis the other staining methods are more suitable, because of their ease of use and inherent superior reproducibility. Fluorescent dyes, e.g. Sypro Ruby, are probably the state-of-the-art, because they combine reproducibility with good linearity and a wide dynamic range [19] . Radioactive metabolic labeling prior to separation allows even lower detection limits [12] , but is rarely feasible for ante-or post-mortem animal or human tissue.
A relatively novel, promising method which combines protein visualization and differential analysis is DIGE, differential gel electrophoresis [20] . In DIGE the samples that are to be compared, e.g. control and diseased, are labeled with fluorescent dyes of different colors before separation. Then both samples are mixed and separated together on the same gel. By imaging and overlaying the two different colors, a direct comparison within the same gel is possible, which alleviates the problems of gelto-gel variability (see below) and thus should facilitate image analysis. The main disadvantage of the method is the need for prelabeling, which requires careful optimization for each sample.
In most cases protein spots of interest are selected by comparison of the 2D gel images of the different states Figs. (1 & 2 ) . The specialized software that is employed for the image analysis of 2D gels has to perform two key operations: spot detection and matching. Owing to the fact that preparation of 2D gels can not be automated yet, there is a certain degree of variability, both with respect to intensity of the spots and their precise location. Therefore, even in the most sophisticated analysis programs, a fair degree of user intervention is still required. A consequence of the variability of 2D gels is that small differences can not be reliably detected. In our hands, with the most homogeneous samples, such as cell line extracts, five replicates per sample will allow reliable detection of twofold changes in spotintensity (not shown). When samples are not homogeneous, such as in most cases when studying animal or human tissue, the variability of the method is usually less significant than the biological variability. In those cases reliable comparisons require a sufficiently large group size rather than a large number of replicates (see also below).
After selection by image analysis, protein spots of interest are excised from the gel and treated with a proteolytic enzyme, which is usually trypsin, to obtain peptides. The conversion to peptides allows efficient recovery from the gel and yields highly accurate mass and sequence information by mass spectrometry, which can not be obtained from the intact protein. For a detailed discussion of MS methods in proteomics, which is beyond the scope of this paper, the reader is referred to one of the reviews in this area [21] . In many cases, the actual protein identification can be based solely on the masses of the different peptides derived from the parent protein spot using MALDI-TOF (matrixassisted laser desorption ionization time-of-flight) mass spectrometry. In MALDI-TOF MS the peptide mixture is co-crystallized with a large excess of a light absorbing matrix, e.g. sinapinic acid. By pulses of laser light the analyte is desorbed and ionized with the help of the matrix, after which the mass measurement can take place. Masses are determined by measuring their flight time to a detector, which is inversely proportional to their mass. By measuring the masses of all the peptides in a proteolytic digest, a unique mass fingerprint is obtained for each protein. The list of masses of peptide fragments from a given protein is then compared to a protein database in which the protein sequences have been converted to a peptide mass list by in silico digestion with the appropriate enzyme. In cases where this approach does not yield results, e.g. because the protein is not in any database or too few peptides could be recovered for a unique assignment, identification has to be attempted by partial sequencing of individual peptides by tandem MS (also called MSMS) methods [22] .
As the name suggests, a tandem MS instrument consists of two mass analyzers. In the first of these, the peptide of interest is separated and selected. Subsequently, the peptide is fragmented by colliding it with nitrogen or argon and the resulting fragments are analyzed in the second mass analyzer. In general, fragmentation occurs at several peptidic amide bonds and thus provides at least partial amino acid sequence information. Sequence information on a single peptide can be enough to unequivocally identify a protein, whereas reliable peptide fingerprinting requires a number of peptide masses.
As mentioned above, in the LC-based peptide separations, the mass spectrometer can be directly coupled after the LC and identification performed, mostly by tandem-MS sequencing.
Protein Characterization
Proteomic studies are generally focused on the identification of a large number of proteins and the degree to which they are actually characterized is often overestimated. In protein identification by peptide mass fingerprinting, an important parameter is the sequence coverage: the proportion of the whole protein that is accounted for by combining all assigned peptides. High-throughput mapping and identification of proteins (see below) is often associated with sequence coverages in the order of 20 -30 %, which is sufficient for unequivocal identification, but at the same time implies that 70 -80% of the amino acids remain uncharacterized. In tandem-MS sequencing, the situation is even more extreme, because small pieces of sequence information are sufficient for identification. If the protein in question was derived from a 2D gel, at least the information on the size and charge of the parent is available. However, in LC-MS analysis of trypsinized cell or tissue extracts [10, 17] , one can not even be certain that the intact parent protein was actually present, without a follow-up experiment to monitor the protein level.
In the ideal case a proteomics experiment encompasses the identification of differentially expressed proteins and their full characterization, in particular with respect to functionally important modifications such as phosphorylation. An illustration of the effort involved is the characterization of stathmin isoforms, derived from a differential proteome study of Taxol-treated versus untreated human B-lymphoma cells [11] . In those cells Taxol induced the upregulation of a number of spots, which were all shown to contain the same protein, stathmin/OP-18. A combination of MS methods and different proteolytic digestions finally resulted in the characterization of a range of different isoforms of stathmin, differing in the number and position of phosphorylated serine residues. This example shows that regardless of the technological advances, characterization is still a slow process, in which usually individual proteins have to be tackled according to a tailor-made strategy. Equally important as the in-depth characterization of single protein species, is an overview of the isoforms for that specific protein. As will be discussed in later, this is particularly true when dealing with heterogeneous samples such as those derived from human tissue, where subtle individual differences occur. Often a differential analysis will reveal differences in one species of a certain protein, while many more might be present in the sample. The ideal method to obtain such an isoform profile is almost always 2D electrophoresis, because of its high resolution. When limited amounts of extracts or antibodies are available or a large number of samples must be profiled, a recently described one-dimensional charge separation [23] can be useful. In this method, proteins are blotted to a membrane after high-resolution iso-electric focusing. In cases such as phosphorylation, where isoforms are separated by charge, this method provides a good alternative to 2D gels, even though the mass resolution is lost.
Imaging Mass Spectrometry
The ultimate goal of a proteomic analysis of any tissue, particularly in brain, is to obtain single-cell resolution. As will be discussed in more detail later, current protein profiling methods almost always require tissue samples, which are homogenates of different cell types. Over the past few years, several methods have been developed to generate protein profiles by MALDI-MS directly from cells, groups of cells and small tissue sections immobilized on a target plate [reviewed in 24] . Frozen tissue sections with a thickness of 12 µm are immobilized onto a metal plate of the type that is commonly used as sample carrier in a MALDI instrument and sprayed with the matrix solution, generally sinapinic acid. The matrix is left to crystallize and the laser is used to 'scan' the whole section and perform MS measurements at every point. Thus it is possible to make true molecular images of most tissues. The resolution of the image is determined by the size of the laser beam, currently as fine as 50 µ m [24] . While the method with the currently used detectors is mainly suitable for the imaging of peptides and small proteins, larger proteins can also be visualized as long as they are relatively abundant [25, 26] . The potential of MALDI imaging is that in theory with each laser shot a comprehensive picture of all molecules present is obtained. For example, in brain one could perform spatially resolved measurements of both neurotransmitters and their receptors simultaneously. Or, in the case of drug treatment an accurate picture of the localization of the compound and its action could be obtained. Until that is possible, there are still important obstacles in terms of mass and image resolution, sensitivity and background that need to be solved, but it is a safe assumption that mass spectrometric imaging is going to play a major role in the analysis of complex tissues.
Protein Chips/Biomarkers
While the aim of proteomic studies generally is to obtain profiling data on as many protein species as possible, there are examples of successful molecular characterization of a disease state with a limited analysis depth. One alternative approach is SELDI (surface enhanced laser desorption ionization) mass spectrometry on ProteinChips® [27] . In this method, protein extracts, often derived from biological fluids, are fractionated on chromatographic surfaces and detected by mass spectrometry, basically using MALDI-TOF MS. So far SELDI has mainly been applied in the classification of different tumors and cancer patients [28] . Compared to 2D PAGE, SELDI is a more rapid method, which has enough sensitivity to extract information even from laser capture microdissected samples [29] . Due to the detection principle used in MALDI, the method is most suited for monitoring peptides and small proteins up to 20 kDa. Although the feasibility is still an open question, the idea of a proteome-based molecular diagnosis of psychiatric disease utilizing biological fluids is very tempting. In contrast to the situation with postmortem tissue, this would permit the analysis of living subjects and correlation of the results with an indepth clinical characterization. Another tool in molecular diagnosis is the protein array. By arraying either antibodies or tissue extracts, it is possible to check for the presence of certain classes of proteins [30] or even for the phosphorylation state of key intermediates in signaling pathways [31] . Whether the latter option can give meaningful information on postmortem samples remains to be shown. In contrast to protein profiling on chips or with gels, protein arrays are closed systems like DNA microarrays, probing for known molecular entities. ProteinChips and protein arrays are not the tools of choice for a comprehensive investigation of molecular mechanisms. The primary applications of both SELDI and protein (antibody) arrays are diagnostic in nature, e.g. discovery of markers for disease or treatment in biofluids [28] or antibodybased monitoring of changes in a predefined subproteome of interest.
Beyond Profiling -Interaction Proteomics
While this review will illustrate that it is now possible to generate vast amounts of protein profiling data of tissue samples, it is important to point out that the 'high-throughput biology' to turn this data into meaningful information on disease mechanisms and biological pathways is almost completely lacking. One route to increase understanding of the important aspects of their biological role is to identify interacting partners and thus to establish the position of the individual proteins within the network of cellular pathways. The method of choice to explore interactions partners of a protein is (co-)immunoprecipitation: the protein of interest is captured from a cell or tissue lysate by an antibody with the expectation that at least some of the interacting partners will remain bound during the process. Subsequently the immune complex can be separated by electrophoresis and the proteins identified. To avoid interference between capturing antibody and interaction partners, the 'bait' protein is often 'tagged' with a synthetic antigen, which can be used for the pull-down. In yeast such 'fishing' experiments with bait proteins have been carried out on a proteome scale, using different combination of tags and high-throughput mass spectrometry for protein identification, resulting in interaction maps with thousands of members [32, 33] . However, subsequent comparison of these data and other interaction data derived from two-hybrid experiments showed that there was very little overlap between the interaction maps, suggesting that all these highthroughput interaction proteomics methods have a large potential for 'false positives' [34] . The conclusion has to be that there is no reliable method for proteome-wide detection of protein complexes, neither in yeast nor in the even more complex situation in mammalian systems.
APPLICATIONS OF PROTEOMICS IN DISEASES OF THE CENTRAL NERVOUS SYSTEM Sample Selection -Postmortem Interval
Sample origin and preparation are key concerns for the validity of (comparative) proteomic analyses with human tissues. In contrast to animal studies, where the trajectory from the living animal through dissection to protein extraction can generally be tightly controlled, the situation with human postmortem samples is much more complex. Intuitively, one would consider the postmortem interval (PMI) to be one of the most critical parameters for obtaining a representative protein or gene expression profile. At the same time reliable data on PMI are not easily obtainable, except in the case of hospitalized patients. In the best cases a good estimate of the duration of the PMI might be available. While that is an important parameter, the actual circumstances during the PMI, especially the ambient temperature, are even more important.
Although a number of differential proteomic analyses with human brain samples have been published [35] [36] [37] [38] [39] [40] [41] , surprisingly little is known about quantitative postmortem changes in the brain protein profile. In human studies these effects can only be deduced from the observed changes and their correlation with PMI, provided that a large enough sample size is used. The findings then have to be extrapolated to zero time, which is never practically obtainable. The published study with the highest number (89) of subjects [35] provides valuable information on the correlation of protein up-or downregulation with a number of variables, but unfortunately not with PMI.
he alternative to a retrospective analysis of protein profiles from human is the use of an animal model. While the kinetics of the changes in brains of rats and mice need not be comparable to those in human, an important advantage of that approach is that a true reference point with a PMI of zero can be obtained. In a study using two-dimensional electrophoresis at standard resolution, Fountoulakis et al. [36] found that in rat brain the majority of postmortem changes occurs after prolonged incubation at room temperature. After 48 h hours or longer several structural proteins, such as spectrin, dynamin, tubulins, actins and GFAP (glial fibrillary acidic protein) were affected. Within the first 24 h only minor effects were visible. In a pilot experiment with high-resolution separation, in which mouse brains were kept up to 24 h at 4 °C or up to 4 h at room temperature, few changes were observed among 1500-2000 protein species in the pH 4-7 or pH 4.5-5.5 interval. Only one protein spot, representing NDRG-2, appeared to change consistently with PMI Fig. (3) . A more extensive study in animals with a brain size comparable to human would be required to obtain representative data, but the available information indicates that the brain proteome is relatively stable within the first 24 h postmortem. Similar data are available for mRNA, which is thought to be less stable than protein under most conditions [42, 43] . The question remains if PMI should be the primary criterion for selection of samples for proteomic analysis. Possibly other parameters of the brain, such as its pH which can be influenced in certain causes of death, are at least as important as the length of the interval. However, comprehensive profiling data to assess the relevance of pH or other variables are not available. Finally, there are reports that extended storage (freezer time) might have an effect on the protein profile as well [35] . Clearly there is a significant lack of data, especially with respect to dynamic processes such as (de)phosphorylation. 
Sample Preparation
High quality protein profiling data requires substantial amounts of material. For a complete analysis on 2D gels, using 6 narrow-range pH gradients in triplicate, a total amount of 15-20 mg of protein would be required (for the 18 gels), corresponding to 250-400 mg of brain tissue. The sensitivity of 2D electrophoresis is currently mainly limited by the protein staining methods. For a differential analysis of a significant number of patients, the only option is a post-separation staining, which is quantitative, linear and easy to reproduce, leaving only fluorescent dyes or Coomassie Blue (see above). Thus proteomic profiling of complex tissues is still a major challenge. Significant changes in one cell type or population in the tissue of interest are 'diluted' by homogenization with other unaffected cell types, and disappear under the threshold of significance [44] . Laser capture microdissection (LCM) provides a potential solution to this problem, by enabling selection of cells of a given type or morphology for dissection [45] . While protein extraction is feasible from fixed, stained and laser-dissected material, the dissection time needed to obtain enough tissue for a single 2D gel ranges from several hours to 2 days [46] . For comprehensive protein profiling of most cell types LCM can not be used, because the sample requirements are far beyond the limitations of the method, especially if cells must be selected singly as opposed to 'cutting' along tissue margins. However, LCM could become of great value in combination with other proteomic methods, such as SELDI [47] , antibody-based profiling [31] as well as in gene expression profiling [48] .
Variability and True Changes
The ultimate challenge of expression profiling of human brain tissue is the discrimination of diseaseassociated changes from individual variation [49] . While sample consistency can be optimized by meticulous selection of samples and careful experimental design, a significant part of the variability is inevitable. At the protein level, the full spectrum of inherent individual variation accumulates, ranging from differences at the transcript level (alternative splicing and polymorphisms) to post-translation modifications (e.g. phosphorylation). Paradoxically, in a profiling experiment transcriptional variations are usually more easily detected at the protein level, because the probes on the widely used oligonucleotide microarrays are not designed to cover the regions which contain single nucleotide polymorphisms (SNPs). Obviously, for discovering patterns of noncoding (silent) SNPs, which might be important for regulation of gene expression rather than for protein function, protein-based methods can not be employed.
In an mRNA profiling experiment the inherent variation is limited to differences in mRNA abundance, whereas a proteomics analysis has additional value in documenting the occurrence of multiple isoforms, each species potentially with a different function or activity [16] . Therefore it is a prerequisite to estimate the overall variation in a sample set prior to the profiling experiment, in order to assess whether the experimental design will allow the detection of true differences. Since no published study has yet fulfilled this requirement, a summary of findings from our laboratory with a set of 20 motor cortex samples from individuals, destined to serve as a control for an equally sized schizophrenia group, is presented in Fig. (4) . In summary, the results of this Fig. (2) ). Each of the 20 samples was run in triplicate and for each sample one gel was selected for this comparison. Spots were matched to an arbitrary reference gel and intensities normalized to correct for differences in protein loading. The graph shows spot intensity (integrated optical density) on the X-axis and the coefficient of variation (CV, standard deviation divided by mean) of spotintensity over all the matched spots on the Y-axis. It shows the expected 'banana' shape, indicating that the variability goes up when the spotintensities approach the limit of detection. Only a limited number of spots above the reliable detection limit (see arrow) show high variability. These 'hypervariable' spots often show a range of isoforms differing from individual to individual (see text and cf. Fig. (5) ). The conclusion from this experiment was that with a group size of 20 individuals variability per se is not an insurmountable hurdle for proteomics analysis using high resolution two-dimensional gel electrophoresis. experiment showed that, while there were distinct and important individual differences, these seemed to be restricted to a limited set of proteins that showed high variability with a CV of over 50%. This 50% CV cutoff was arbitrarily chosen, based on the experience that variability using well standardized samples such as those derived from cell lines are in the range of 20%. The majority of proteins appears to be relatively stable across a group of 20 individuals Fig. (4 ) . The conclusion from this experiment was that the individual variability per se does not pose insurmountable problems for the analysis, when the group size is adequate. We decided to pick as many of the 'hypervariable' spots as possible, in order to flag those proteins as potentially risky for association with a specific group. At the same time, the expression patterns of certain protein isoforms can be of utmost importance for discriminating subpopulations in a sample set, even if there is no overall association with a disease group. Actually, in view of the complexity of psychiatric diseases [3, 50] , it will probably remain an exception to find expression difference with such high penetrance that they will survive rigorous group statistics. A good illustration of a hypervariable protein with a large 'false positive' potential is the GFAP. Among the few reported proteome analyses of disease-related changes in human brain, two reports claim that changes in GFAP expression are associated with schizophrenia, depression and bipolar disorder [35] or Alzheimer's disease [37] . In our pilot experiment Fig. (4) , GFAP was the most heterogeneous of the hypervariable proteins, being present in at least 14 different spots, some of them representing isoforms of the 50 kDa complete protein, others the known 36 kDa fragment [51] . Regardless of the presence of neurological disorders, the expression of GFAP isoforms varies so strongly between individuals Fig. (5 a ) that differences observed in small groups are due to individual variation more likely than to a disease state. In a larger sample set of 20 controls and 20 samples from a schizophrenia group, the full spectrum of isoforms as detected by an antibody showed around 20 bands in the pH range from 4-7 alone Fig. (5b) . Although others have noted these variations as well at a lower resolution [37] , a more rigorous follow-up (cf. Fig. (5b) ) is required for a correct interpretation of differential analyses. Although the issue of individual variation is mostly overlooked in published differential expression studies, a few strategies have emerged to deal with variability. One efficient way of lowering the noise in a population is pooling of individual samples, which has the concomitant advantage of drastically reducing the number of samples to be analyzed. When the goal of an experiment is to find consistent differences between groups and individual profiles are of secondary interest, pooling is a good strategy. However, in most if not all studies with human subjects, the value lies in obtaining the individual information, particularly in complex diseases, where no single patient will have the same symptoms, responses to medication or ante mortem correlated data. In our studies with human samples, we always analyze both individual and pooled samples. Inclusion of pools in a differential display experiment usually takes little additional effort and can help to rapidly single out common disease-specific changes, where they exist. Another approach to amplify differences, which are not obvious from group comparisons, is paired analysis: control and matched diseased samples are analyzed as pairs instead of comparing the whole disease group versus the controls [44, 52] . While pairing decreases sample complexity by matching gender, age, ethnicity and/or medication, it is mostly arbitrary when dealing with different individuals. Pairing is appropriate when comparing multiple samples from one and the same individual. In the case of a complex psychiatric disease, there is no way of telling a priori, whether any of the 'macroscopic factors' used for selecting the pairs is relevant to the disease or to its manifestation in the protein or gene expression profile. In a sense proper pairing can only be done after the analysis, based on the expression profile of many thousand genes and proteins, instead of on arbitrary characteristics.
Neuroproteomics and Psychiatric Illnesses
The first 'neuroproteomic' studies were not done on brain extracts but on body fluids presumed to reflect the dynamic changes in the brain: cerebrospinal fluid (CSF) and blood. The goal of these studies was to generate a reference atlas of the respective tissue, resulting in a CSF database with over 900 identified protein spots [53] . At the same time proteomic analysis of CSF was also used to identify possible markers for molecular diagnosis of brain disease [54, 55] .
More recently protein maps of animal or human brain regions have been generated again aiming to provide a reference map for further studies. Protein maps [12, 40, 56, 57] are useful to illustrate the power of current proteomics technology, which allow separation of thousands of proteins on 2D gels and rapid identification of many of them by automated MS methods. On the other hand their general use is very limited because, unless the exact same brain region and sample preparation is used, the comigration of a spot on a 2D gel is never a guarantee for the same identity. Moreover, a 'spot' may be comprised of several comigrating proteins that are not resolved. From the small number of published studies where proteomic technologies have been applied to a true differential analysis with samples derived from psychiatric patients, it appears that some of the technical and practical limitations discussed previously may have discouraged investigators. One of the most extensive studies was performed by Johnston-Wilson et. al. [35] , who analyzed Brodmann Area 10 from 89 individuals, including psychiatric patients suffering from schizophrenia, bipolar disorder, and depression. The differential analysis was performed with 2D gels in a single pH gradient from pH 4 -7. Despite the limited depth of analyses, the paper merits value, because of the large group sizes and the thorough statistical analysis, not only with respect to group differences but also regarding a wide range of factors other than the disease that might influence the protein profiles, such as age, substance abuse and freezer time. The most variable protein was the glial fibrillary acidic protein GFAP (cf. Fig. (5) ). Several isoforms were found to be associated with depression, schizophrenia and bipolar disorder as well as with the external factor freezer time. In accordance with our observations, the analysis shows that GFAP isoforms are highly variable and that in most cases a small number of individuals within the respective group is responsible for the statistical difference. As the authors suggest, post-translational modifications including phosphorylation might be responsible for these different isoforms, which might also explain the variability associated with storage time. Unfortunately this hypothesis can not be tested, since no information is provided about postmortem intervals. These results stress the importance of obtaining a complete isoform pattern of differentially expressed proteins in order to be able to distinguish 'normal' variation from disease-related changes.
In a series of 4 papers, based on one and the same sample set, Edgar et. al. [38] [39] [40] [41] investigate alterations in the protein profile of the hippocampus associated with schizophrenia. Again 2D electrophoresis was employed in single, lower resolution pH 3-10 gradient, in which approximately 500 protein spots could be matched across the whole sample set of 7 controls and 7 patients. A clustering of differentially expressed proteins at the long arm of chromosome 6 is suggested, but little information on the magnitude of these differences is provided. The authors do not address the question about the relevance of data from such small groups or on the effects of 'external' influences such as the relatively long PMI of their samples. Typically, the previously mentioned proteomic studies have generated the differential data, but did not follow up to reconfirm the differences with an independent method.
A recent Swedish study [58] shows an interesting direction in which proteomics could contribute to understanding of psychiatric disease. This paper addresses the changes in protein and gene profiles in the cerebral cortex of rats treated with MK-801, an NMDA receptor antagonist. Interestingly, the work forges clinical correlates with psychotomimetic drugs of abuse, in an emerging direction towards corroborating a glutamatergic input to the phenotype of schizophrenia, as opposed to the traditional dopamine hypothesis. However, the protein profiling appears to have very limited coverage, possibly partly due to the fact that RNA and proteins were sequentially extracted from the same samples.
CONCLUSIONS AND OUTLOOK
Large-scale gene and protein expression profiling have opened up new vistas toward unraveling biological pathways or disease states at the molecular level. These analyses no longer aim to prove or disprove hypothetical disease mechanisms but to deduce the underlying molecular pathology de novo based upon the observed changes. Particularly in psychiatric diseases, genomic and proteomic approaches hold the promise of a completely novel insight into the multifactorial disease process and the discovery of new therapeutic targets. The aim of this paper was to discuss the possible contribution of current protein profiling technologies to the analysis of molecular mechanisms in psychiatric disorders and to review the progress that has been reported in this area. The clear advantage of a proteomic approach is that it deals with the 'phenotype' of the disease in the brain: the result of a complex interaction between genetic predisposition and environmental modulation [3, 50] .
At this point it is important to realize that there is an interaction between the molecular phenotype at the protein expression level and the clinical phenotype, which determines the classification of the patient to the disease group that is being analyzed. Undertaking investigations for creating a prognostic indicator for a multigenic disease such as schizophrenia begins with the existing indicators of diagnosis, such as those presented by the DSM-IV and/or ICD-10. This yields a population for whom careful controls of unaffecteds are utilized to examine differences that may be ascribed to the disease. Though the above criteria for assessment are utilized by clinicians, additional modes of validating neuropsychiatric illnesses are required. The errant supposition lies in the adherence to the "definitive" indicators as the ultimate diagnostic tool. Correlative data in addition to other factors (such as laboratory, follow-up and family studies) can be used to aid in distinguishing disorders [59] .
Unlike inborn errors of metabolism neuropsychiatric disorders are multigenic, and the quest involves correlating symptoms to their molecular bases. Already a more robust classification of these phenotypes, if they correlate with different subgroups of patients, would be a major step forward for a disease like schizophrenia, where currently it appears as if familial genetic 'hotspots' are found on almost every chromosome with corresponding different facets of the disease phenotype. Improved 'clustering' of patients would enable the in-depth investigation of more homogeneous patient groups, with increased chances of finding common pathways to the disease. Of course, understanding the underlying molecular mechanisms used by neurons with respect to their architecture, signaling cascades and synaptic transmission, may provide insights into pathological mechanisms occurring in psychiatric disorders by examining a larger number of specimens. Validation occurs with the clinical sequelae to confirm that the targeted (post-translationally modified) gene products are involved with the symptomology and etiology associated with the disease. This feedback upon the diagnosis and then prognosis, will hopefully lead down the ultimate road to treatment. What is required is the ability to compare and contrast the utility of the diagnosis by proscribed tenets with the validity of the singular characterization of the disease that is studied [60] .
As long as the molecular phenotypes will have to be determined on postmortem tissue, an in-depth evaluation of the correlation with clinical information will remain a major challenge. Unfortunately, in the absence of valid animal models proteomic analyses and other expression profiling techniques will depend on postmortem tissue for some time to come. The inherent sample variability, both natural and artificial, is a major challenge for the available protein separation and differential analysis methods. When comparing the primary methods for protein and mRNA profiling, the situation is slightly different at the transcriptome level. While the biggest issue of 2D gels is the matching of the protein spot patterns from sample to sample, the predefined arrangement of the probes on the different types of microarrays ensures accurate matching between arrays. Since in the near future the complete human transcriptome should be addressable by a new generation of microarrays, the question arises whether it is still worthwhile to pursue global profiling approaches at the protein level?
The most cogent arguments in favor involve the limited correlation between mRNA and protein levels and the post-translational events that can not be monitored in any other way. One clear observation from the published mRNA profiling studies [44, 52, 61] , is that the quantitative changes associated with psychiatric disease are very small. Hardly any change crosses the twofold threshold that is considered by many investigators to be at the low end of what can be considered significant. This might also explain why there is very little overlap between the studies. One can argue that a consistent pattern of small changes can be very significant [52] , but the question remains how much of that pattern remains at the protein level, a question that none of the microarray studies can answer. Regarding proteomics in terms of posttranslational events, there is still a clear lack of knowledge regarding the stability of some important modifications, most notably phosphorylation. It is hard to imagine that phosphorylation patterns are stable during prolonged postmortem intervals, while the activation states of proteins in vivo can change within minutes. In view of the problems associated with global expression profiling, a more promising approach might be to focus on molecular markers of disease subtypes. Such markers might not require a comprehensive profiling effort, which could be carried out on biological fluids obtained from clinically wellcharacterized patients so that clustering of the molecular phenotypes becomes meaningful for the disease states.
For any realistic prospect of success, a molecular characterization of psychiatric disease should be as comprehensive and complementary with respect to information content as possible, at the genomic level for patterns of SNPs [62, 63] within and outside of coding regions, at the transcriptomics level for rapid and comprehensive gene expression profiling and at the proteomics level for the profiling of the ultimate disease phenotype. In all studies the most important factor is the commitment to analyze sufficiently large numbers of samples of which enough background information is known to correlate findings with the biology of the disease under query.
So far neither proteomic nor transcriptomic profiling studies have been able to provide truly novel insights in psychiatric disease. Besides the inherent problems associated with the postmortem samples, the absence of tools to validate findings is the biggest obstacle for successful differential analyses of mental illnesses. Consequently, profiling studies usually stop after generating a list of differences, although that list should not be the endpoint for exploration, but the starting point of the validation process. Therefore profiling of animal models of disease [58] is as necessary as analyzing human disease tissue. Only the combination will bring us closer to valid animal models and ultimately to new therapeutic targets for psychiatric disease.
